Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9692.7222
Address
Level 4 100 Albert Road South Melbourne, Victoria (VIC) 3205
Description
Prescient Therapeutics Ltd. is a biopharmaceutical company, which engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. It develops immune therapeutics based upon its Co-X-Gene and fowlpox virus delivery technologies. The company was founded on May 22, 1986, and is headquartered in South Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.04 - 0.1
Trade Value (12mth)
AU$12,307.00
1 week
4.55%
1 month
12.2%
YTD
-32.35%
1 year
-41.03%
All time high
184.85
EPS 3 yr Growth
50.00%
EBITDA Margin
N/A
Operating Cashflow
-$7m
Free Cash Flow Return
-33.50%
ROIC
-37.30%
Interest Coverage
N/A
Quick Ratio
8.10
Shares on Issue (Fully Dilluted)
805m
HALO Sector
Healthcare
Next Company Report Date
01-Sep-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
05 September 24 |
PTX Presentation
×
PTX Presentation |
26 August 24 |
Appendix 4E and 2024 Annual Report
×
Appendix 4E and 2024 Annual Report |
26 August 24 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
31 July 24 |
June 2024 Quarterly Update and Appendix 4C
×
June 2024 Quarterly Update and Appendix 4C |
05 July 24 |
Initial Director's Interest Notice
×
Initial Director's Interest Notice |
04 July 24 |
PTX appoints Dr Gavin Shepherd as Non-Executive Director
×
PTX appoints Dr Gavin Shepherd as Non-Executive Director |
04 June 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
04 June 24 |
Notification of cessation of securities - PTX
×
Notification of cessation of securities - PTX |
20 May 24 |
PTX invited to present at international lymphoma forum
×
PTX invited to present at international lymphoma forum |
30 April 24 |
March 2024 Quarterly Update and Appendix 4C
×
March 2024 Quarterly Update and Appendix 4C |
08 April 24 |
PTX100 Ph1b results to be presented at specialist congress
×
PTX100 Ph1b results to be presented at specialist congress |
05 April 24 |
Notification of cessation of securities - PTX
×
Notification of cessation of securities - PTX |
23 February 24 |
Appendix 4D and Half Year Financial Report
×
Appendix 4D and Half Year Financial Report |
31 January 24 |
December 2023 Quarterly Update and Appendix 4C
×
December 2023 Quarterly Update and Appendix 4C |
18 December 23 |
PTX-100 Spotlight Presentation
×
PTX-100 Spotlight Presentation |
11 December 23 |
PTX-100 Ph1b results show excellent safety & efficacy in TCL
×
PTX-100 Ph1b results show excellent safety & efficacy in TCL |
28 November 23 |
Prescient Receives $2.4 Million R&D Tax Rebate
×
Prescient Receives $2.4 Million R&D Tax Rebate |
16 November 23 |
Chair and CEO AGM Presentation
×
Chair and CEO AGM Presentation |
16 November 23 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
06 November 23 |
PTX-100 abstract published online on ASH website
×
PTX-100 abstract published online on ASH website |
31 October 23 |
September 2023 Quarterly Update and Appendix 4C
×
September 2023 Quarterly Update and Appendix 4C |
17 October 23 |
PTX results to be presented at world's largest blood meeting
×
PTX results to be presented at world's largest blood meeting |
13 October 23 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
31 August 23 |
Section 708A Cleansing Notice
×
Section 708A Cleansing Notice |
31 August 23 |
Application for quotation of securities - PTX
×
Application for quotation of securities - PTX |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.